vimarsana.com
Home
Live Updates
Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer : vimarsana.com
Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer
/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA...
Related Keywords
Cambridge
,
Cambridgeshire
,
United Kingdom
,
Thomas Mccauley
,
Jason Braco
,
Eva Stroynowski
,
Mahesh Karande
,
Omega Epigenomic
,
Linkedin
,
Twitter
,
American Society Of Gene Cell Therapy
,
Nitto Denko Corporation
,
Prnewswire Omega Therapeutics Inc
,
Nasdaq
,
Company Pioneering
,
Lifesci Communications
,
Second Development
,
Second Development Candidate Arising
,
Omega Epigenomic Controller
,
Investigational New Drug
,
Cell Therapy
,
Annual Meeting
,
Chief Scientific Officer
,
Chief Executive Officer
,
Flagship Pioneering
,
Omega Epigenomic Controllers
,
Precision Genomic Control
,
Private Securities Litigation Reform Act
,
Quarterly Report
,
Cancer Res Clin Oncol
,
Media Contact
,
Omega Therapeutics
,
vimarsana.com © 2020. All Rights Reserved.